-
Information-Publications
-
GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancerDetails
-
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1Details
-
D-mannose promotes the degradation of IDH2 through upregulation of RNF185 and suppresses breast cancerDetails
-
TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potentialDetails
-
FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammationDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands